Emmanuel Papadakis
Stock Analyst at Deutsche Bank
(1.48)
# 3,115
Out of 4,829 analysts
41
Total ratings
47.37%
Success rate
-0.58%
Average return
Main Sectors:
Stocks Rated by Emmanuel Papadakis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $95 → $150 | $92.87 | +61.52% | 9 | Sep 19, 2024 | |
| MRNA Moderna | Upgrades: Hold | $85 → $80 | $24.25 | +229.90% | 8 | Aug 6, 2024 | |
| GRFS Grifols | Downgrades: Sell | n/a | $7.10 | - | 2 | Mar 12, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $67.57 | - | 3 | Feb 8, 2024 | |
| ALVO Alvotech | Maintains: Hold | $8 → $12 | $9.63 | +24.61% | 2 | Mar 7, 2023 | |
| SNY Sanofi | Upgrades: Hold | n/a | $49.90 | - | 4 | Aug 12, 2022 | |
| NVO Novo Nordisk | Upgrades: Buy | n/a | $65.77 | - | 4 | Mar 16, 2022 | |
| CVAC CureVac | Initiates: Hold | $35 | $3.49 | +902.87% | 1 | Oct 22, 2021 | |
| NVS Novartis AG | Downgrades: Sell | n/a | $108.70 | - | 3 | Sep 20, 2021 | |
| ARGX argenx SE | Initiates: Hold | n/a | $549.27 | - | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $36.62 | - | 4 | Feb 4, 2021 |
BioNTech SE
Sep 19, 2024
Maintains: Buy
Price Target: $95 → $150
Current: $92.87
Upside: +61.52%
Moderna
Aug 6, 2024
Upgrades: Hold
Price Target: $85 → $80
Current: $24.25
Upside: +229.90%
Grifols
Mar 12, 2024
Downgrades: Sell
Price Target: n/a
Current: $7.10
Upside: -
AstraZeneca
Feb 8, 2024
Downgrades: Hold
Price Target: n/a
Current: $67.57
Upside: -
Alvotech
Mar 7, 2023
Maintains: Hold
Price Target: $8 → $12
Current: $9.63
Upside: +24.61%
Sanofi
Aug 12, 2022
Upgrades: Hold
Price Target: n/a
Current: $49.90
Upside: -
Novo Nordisk
Mar 16, 2022
Upgrades: Buy
Price Target: n/a
Current: $65.77
Upside: -
CureVac
Oct 22, 2021
Initiates: Hold
Price Target: $35
Current: $3.49
Upside: +902.87%
Novartis AG
Sep 20, 2021
Downgrades: Sell
Price Target: n/a
Current: $108.70
Upside: -
argenx SE
Jul 23, 2021
Initiates: Hold
Price Target: n/a
Current: $549.27
Upside: -
Feb 4, 2021
Downgrades: Sell
Price Target: n/a
Current: $36.62
Upside: -